(77 days)
Not Found
Not Found
No
The summary describes a standard immunoassay with visual interpretation and does not mention any AI/ML components or processes.
No
This device is an in-vitro diagnostic test for detecting FSH levels, not a device used for therapy or treatment.
Yes
The "Intended Use / Indications for Use" states that the device is an "in-vitro diagnostic screen" and that "This kit provides a preliminary result for the detection/presence of FSH in urine." This directly indicates its diagnostic purpose.
No
The device is an in-vitro diagnostic kit that uses immunoassay technology to detect FSH in urine, which involves physical components and chemical reactions, not solely software.
Yes, based on the provided information, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The "Intended Use / Indications for Use" section explicitly states: "The Moments Menopause Check is an in-vitro diagnostic screen for the detection of FSH (follicle stimulating hormone) in urine." This directly identifies it as an in-vitro diagnostic device.
- Device Description: The "Device Description" further clarifies that it's an "Immunoassay for the qualitative detection FSH (follicle stimulating hormone) in urine." Immunoassays performed on biological samples like urine are a common type of in-vitro diagnostic test.
- Sample Type: The test is performed on urine, which is a biological sample collected from the body but tested outside the body (in vitro).
The other sections like "Mentions image processing," "Mentions AI," "Input Imaging Modality," "Anatomical Site," "Indicated Patient Age Range," "Description of the training set," "Description of the test set," "Summary of Performance Studies," "Key Metrics," "Predicate Device(s)," and "Reference Device(s)" provide additional details about the device and its performance, but the core identification as an IVD comes from the explicit statement in the intended use and the nature of the test described.
N/A
Intended Use / Indications for Use
The Moments Menopause Check is a rapid, qualitative immunoassay for the detection of the FSH in urine. The minimum detectable concentration for this test is 25 mIU/ml. This assay is intended for use in the home to assist in the early detection of menopause.
The Moments Menopause Check is an in-vitro diagnostic screen for the detection of FSH (follicle stimulating hormone) in urine. Change in FSH levels may be associated with stages in menopause. This kit provides a preliminary result for the detection/presence of FSH in urine. It is intended for over-the-counter sales.
Product codes
CGJ
Device Description
Immunoassay for the qualitative detection FSH (follicle stimulating hormone) in urine
The Moments Menopause Check, like many commercially available FSH Technology: screening test kits, qualitatively measures the presence of FSH by visual color sandwich one step immunoassay technology. Examples of such predicate devices include the Synova Menocheck and the Applied Biotech SureStep FSH (San Diego, CA 92121). All of the above devices rely on the basic immunochemical sandwich assay principle of recognition and formation of specific antibody / target analyte / antibody / complexes.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
home
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
The product performance characteristics of the TBD Menopause Check Performance: were evaluated in a clinical sample correlation study and a blind labeled spiked study. The results of these studies demonstrate the Moments Menopause Check to be substantially equivalent to the reported performance characteristics of other commercially available tests for the qualitative detection of the FSH in urine. Laboratory studies, using clinical specimens, produced a 98% correlation when compared to the predicate devices. A consumer study was also performed. In it the Moments Menopause Check exhibited excellent overall accuracy (97%) in the hands of lay users.
Key Metrics
98% correlation, 97% overall accuracy
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1300 Follicle-stimulating hormone test system.
(a)
Identification. A follicle-stimulating hormone test system is a device intended to measure follicle-stimulating hormone (FSH) in plasma, serum, and urine. FSH measurements are used in the diagnosis and treatment of pituitary gland and gonadal disorders.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
0
MAY 2 0 2004
K 040575
510 (k) SUMMARY AS REQUIRED BY SECTION 807.92(C)
ldentification: Moments Menopause Check (Models 9111 and 9112)
Description: Immunoassay for the qualitative detection FSH (follicle stimulating hormone) in urine
Name Of Manufacturer:
Phamatech 10151 Barnes Canvon Road San Diego, California 92121, USA
Intended Use: The Moments Menopause Check is a rapid, qualitative immunoassay for the detection of the FSH in urine. The minimum detectable concentration for this test is 25 mIU/ml. This assay is intended for use in the home to assist in the early detection of menopause.
The Moments Menopause Check, like many commercially available FSH Technology: screening test kits, qualitatively measures the presence of FSH by visual color sandwich one step immunoassay technology. Examples of such predicate devices include the Synova Menocheck and the Applied Biotech SureStep FSH (San Diego, CA 92121). All of the above devices rely on the basic immunochemical sandwich assay principle of recognition and formation of specific antibody / target analyte / antibody / complexes.
The product performance characteristics of the TBD Menopause Check Performance: were evaluated in a clinical sample correlation study and a blind labeled spiked study. The results of these studies demonstrate the Moments Menopause Check to be substantially equivalent to the reported performance characteristics of other commercially available tests for the qualitative detection of the FSH in urine. Laboratory studies, using clinical specimens, produced a 98% correlation when compared to the predicate devices. A consumer study was also performed. In it the Moments Menopause Check exhibited excellent overall accuracy (97%) in the hands of lay users.
Conclusion: For the reasons mentioned above, it may be concluded that the Phamatech Moments Menopause Check is substantially equivalent to a variety of detection tests currently in commercial distribution and is safe in the hands of the lay user.
1
Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of an eagle with three curved lines representing its wings.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
MAY 2 0 2004
Mr. Carl A. Mongiovi Vice President Phamatech, Inc. 10151 Barnes Canyon Road San Diego, CA 92121
Re: K040575
Trade/Device Name: Moments Menopause Check (Models 9111 and 9112) Regulation Number: 21 CFR 862.1300 Regulation Name: Follicle-stimulating hormone test system Regulatory Class: Class I Product Code: CGJ Dated: February 5, 2004 Received: March 16, 2004
Dear Mr. Mongiovi:
We have reviewed your Scction 510(k) promarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the l'edcral Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Codc of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
2
Page 2
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours.
Jean M. Cooper, MS, DVM.
Jean M. Cooper, MS, D.V.M. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
3
INDICATIONS FOR USE
Applicant: Phamatech
510 (k) Number (if known): K040575
Device Name: Moments Menopause Check (Models 9111 and 9112)
Indications for Use:
The Moments Menopause Check is an in-vitro diagnostic screen for the detection of FSH (follicle stimulating hormone) in urine. Change in FSH levels may be associated with stages in menopause. This kit provides a preliminary result for the detection/presence of FSH in urine. It is intended for over-the-counter sales.
Prescription Use: Part 21 CFR 801 Subpart D AND/OR
Over the Counter: X 21 CFR 807 Subpart C
Concurrence of CDRH Office of In Vitro Diagnostic Devices (OIVD)
Rate Chucker for Coral Basin
Division Sign-Off
Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) 040575
Page 1 of 1